ID1 and ID3 Regulate the Self-Renewal Capacity of Human Colon Cancer-Initiating Cells through p21

Cancer Cell

Volumn 21, Issue 6, 2012, Pages 777-792

  O'Brien, Catherine A ^a,b,c   Kreso, Antonija ^a,c   Ryan, Paul ^d   Hermans, Karin G ^a   Gibson, Lianne ^a   Wang, Yadong ^a   Tsatsanis, Andrew ^a   Gallinger, Steven ^b,e   Dick, John E ^a,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d BON SECOURS HOSPITAL   (Ireland)

^e MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 3; OXALIPLATIN; PROTEIN P21;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL RENEWAL; CELL STRESS; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

EID: 84862143004     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.04.036     Document Type: Article

References (67)

1. Abbas T., Dutta A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9:400-414.
2. Alberts S.R., Wagman L.D. Chemotherapy for colorectal cancer liver metastases. Oncologist 2008, 13:1063-1073.
3. Al-Hajj M., Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 2004, 23:7274-7282.
4. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
5. Anido J., Sáez-Borderías A., Gonzàlez-Juncà A., Rodón L., Folch G., Carmona M.A., Prieto-Sánchez R.M., Barba I., Martínez-Sáez E., Prudkin L., et al. TGF-β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 2010, 18:655-668.
6. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
7. Bene A., Chambers T.C. p21 functions in a post-mitotic block checkpoint in the apoptotic response to vinblastine. Biochem. Biophys. Res. Commun. 2009, 380:211-217.
8. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
9. Bunz F., Dutriaux A., Lengauer C., Waldman T., Zhou S., Brown J.P., Sedivy J.M., Kinzler K.W., Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282:1497-1501.
10. Chau I., Cunningham D. Treatment in advanced colorectal cancer: what, when and how?. Br. J. Cancer 2009, 100:1704-1719.
11. Cheng T., Rodrigues N., Shen H., Yang Y., Dombkowski D., Sykes M., Scadden D.T. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000, 287:1804-1808.
12. Cheung H.W., Ling M.T., Tsao S.W., Wong Y.C., Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004, 25:881-887.
13. Ciarrocchi A., Jankovic V., Shaked Y., Nolan D.J., Mittal V., Kerbel R.S., Nimer S.D., Benezra R. Id1 restrains p21 expression to control endothelial progenitor cell formation. PLoS One 2007, 2:e1338.
14. Cicalese A., Bonizzi G., Pasi C.E., Faretta M., Ronzoni S., Giulini B., Brisken C., Minucci S., Di Fiore P.P., Pelicci P.G. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 2009, 138:1083-1095.
15. Dalerba P., Dylla S.J., Park I.K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:10158-10163.
16. Dick J.E. Stem cells: self-renewal writ in blood. Nature 2003, 423:231-233.
17. Dick J.E. Stem cell concepts renew cancer research. Blood 2008, 112:4793-4807.
18. Dylla S.J., Beviglia L., Park I.K., Chartier C., Raval J., Ngan L., Pickell K., Aguilar J., Lazetic S., Smith-Berdan S., et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008, 3:e2428.
19. Fong S., Itahana Y., Sumida T., Singh J., Coppe J.P., Liu Y., Richards P.C., Bennington J.L., Lee N.M., Debs R.J., Desprez P.Y. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc. Natl. Acad. Sci. USA 2003, 100:13543-13548.
20. Fong S., Debs R.J., Desprez P.Y. Id genes and proteins as promising targets in cancer therapy. Trends Mol. Med. 2004, 10:387-392.
21. Gorospe M., Wang X., Guyton K.Z., Holbrook N.J. Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. Mol. Cell. Biol. 1996, 16:6654-6660.
22. Gray M.J., Dallas N.A., Van Buren G., Xia L., Yang A.D., Somcio R.J., Gaur P., Mangala L.S., Vivas-Mejia P.E., Fan F., et al. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 2008, 27:7192-7200.
23. Gupta G.P., Perk J., Acharyya S., de Candia P., Mittal V., Todorova-Manova K., Gerald W.L., Brogi E., Benezra R., Massagué J. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc. Natl. Acad. Sci. USA 2007, 104:19506-19511.
24. He S., Nakada D., Morrison S.J. Mechanisms of stem cell self-renewal. Annu. Rev. Cell Dev. Biol. 2009, 25:377-406.
25. Hermann P.C., Huber S.L., Herrler T., Aicher A., Ellwart J.W., Guba M., Bruns C.J., Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
26. Hollnagel A., Oehlmann V., Heymer J., Rüther U., Nordheim A. Id genes are direct targets of bone morphogenetic protein induction in embryonic stem cells. J. Biol. Chem. 1999, 274:19838-19845.
27. Hope K.J., Jin L., Dick J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat. Immunol. 2004, 5:738-743.
28. Hu H., Han H.Y., Wang Y.L., Zhang X.P., Chua C.W., Wong Y.C., Wang X.F., Ling M.T., Xu K.X. The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells. Oncol. Rep. 2009, 21:1053-1059.
29. Huang E.H., Hynes M.J., Zhang T., Ginestier C., Dontu G., Appelman H., Fields J.Z., Wicha M.S., Boman B.M. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res. 2009, 69:3382-3389.
30. Jankovic V., Ciarrocchi A., Boccuni P., DeBlasio T., Benezra R., Nimer S.D. Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 2007, 104:1260-1265.
31. Kharas M.G., Lengner C.J., Al-Shahrour F., Bullinger L., Ball B., Zaidi S., Morgan K., Tam W., Paktinat M., Okabe R., et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat. Med. 2010, 16:903-908.
32. Kleeff J., Ishiwata T., Friess H., Büchler M.W., Israel M.A., Korc M. The helix-loop-helix protein Id2 is overexpressed in human pancreatic cancer. Cancer Res. 1998, 58:3769-3772.
33. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., Clouthier S.G., Wicha M.S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7:e1000121.
34. Kreso A., O'Brien C.A. Colon cancer stem cells. Curr. Protoc. Stem Cell Biol. 2008, 7:3.1.1-3.1.12.
35. Kuremsky J.G., Tepper J.E., McLeod H.L. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2009, 74:673-688.
36. Lee J.Y., Kang M.B., Jang S.H., Qian T., Kim H.J., Kim C.H., Kim Y., Kong G. Id-1 activates Akt-mediated Wnt signaling and p27(Kip1) phosphorylation through PTEN inhibition. Oncogene 2009, 28:824-831.
37. Li B., Cheung P.Y., Wang X., Tsao S.W., Ling M.T., Wong Y.C., Cheung A.L. Id-1 activation of PI3K/Akt/NFkappaB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis 2007, 28:2313-2320.
38. Lin C.Q., Singh J., Murata K., Itahana Y., Parrinello S., Liang S.H., Gillett C.E., Campisi J., Desprez P.Y. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res. 2000, 60:1332-1340.
39. Lin P.Y., Fosmire S.P., Park S.H., Park J.Y., Baksh S., Modiano J.F., Weiss R.H. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol. Cancer 2007, 6:16.
40. Ling M.T., Lau T.C., Zhou C., Chua C.W., Kwok W.K., Wang Q., Wang X., Wong Y.C. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis 2005, 26:1668-1676.
41. Lyden D., Young A.Z., Zagzag D., Yan W., Gerald W., O'Reilly R., Bader B.L., Hynes R.O., Zhuang Y., Manova K., Benezra R. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401:670-677.
42. Mahyar-Roemer M., Roemer K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001, 20:3387-3398.
43. Meteoglu I., Meydan N., Erkus M. Id-1: regulator of EGFR and VEGF and potential target for colorectal cancer therapy. J. Exp. Clin. Cancer Res. 2008, 27:69.
44. Morrison S.J., Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006, 441:1068-1074.
45. Morrison S.J., Spradling A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 2008, 132:598-611.
46. Nam H.S., Benezra R. High levels of Id1 expression define B1 type adult neural stem cells. Cell Stem Cell 2009, 5:515-526.
47. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
48. O'Brien C.A., Kreso A., Dick J.E. Cancer stem cells in solid tumors: an overview. Semin. Radiat. Oncol. 2009, 19:71-77.
49. Ouyang X.S., Wang X., Lee D.T., Tsao S.W., Wong Y.C. Over expression of ID-1 in prostate cancer. J. Urol. 2002, 167:2598-2602.
50. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., Bernard L., Viale G., Pelicci P.G., Di Fiore P.P. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
51. Perry S.S., Zhao Y., Nie L., Cochrane S.W., Huang Z., Sun X.H. Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. Blood 2007, 110:2351-2360.
52. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
53. Rau B., Sturm I., Lage H., Berger S., Schneider U., Hauptmann S., Wust P., Riess H., Schlag P.M., Dörken B., Daniel P.T. Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J. Clin. Oncol. 2003, 21:3391-3401.
54. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
55. Ruzinova M.B., Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003, 13:410-418.
56. Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan Q., Jordan S., Duncan L.M., Weishaupt C., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
57. Schindl M., Oberhuber G., Obermair A., Schoppmann S.F., Karner B., Birner P. Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer. Cancer Res. 2001, 61:5703-5706.
58. Schindl M., Schoppmann S.F., Ströbel T., Heinzl H., Leisser C., Horvat R., Birner P. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin. Cancer Res. 2003, 9:779-785.
59. Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
60. Sharma R.R., Ravikumar T.S., Raimo D., Yang W.L. Induction of p21WAF1 expression protects HT29 colon cancer cells from apoptosis induced by cryoinjury. Ann. Surg. Oncol. 2005, 12:743-752.
61. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
62. Swarbrick A., Roy E., Allen T., Bishop J.M. Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc. Natl. Acad. Sci. USA 2008, 105:5402-5407.
63. Tian H., Wittmack E.K., Jorgensen T.J. p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res. 2000, 60:679-684.
64. Todaro M., Perez Alea M., Scopelliti A., Medema J.P., Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008, 7:309-313.
65. van de Wetering M., Sancho E., Verweij C., de Lau W., Oving I., Hurlstone A., van der Horn K., Batlle E., Coudreuse D., Haramis A.P., et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002, 111:241-250.
66. Vermeulen L., Todaro M., de Sousa Mello F., Sprick M.R., Kemper K., Perez Alea M., Richel D.J., Stassi G., Medema J.P. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl. Acad. Sci. USA 2008, 105:13427-13432.
67. Viale A., De Franco F., Orleth A., Cambiaghi V., Giuliani V., Bossi D., Ronchini C., Ronzoni S., Muradore I., Monestiroli S., et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009, 457:51-56.